JORIS DE MAEYER

Joris De Maeyer stands as a pivotal figure in the European life sciences venture capital landscape, serving as a Partner at Bioqube Ventures. In this role, he is instrumental in identifying, evaluating, and nurturing early-stage biotech and therapeutic companies poised to revolutionize healthcare. His work at Bioqube Ventures underscores the firm's commitment to investing in cutting-edge scientific innovation and translating groundbreaking research into tangible medical solutions.

At Bioqube Ventures, Joris De Maeyer's investment focus is sharply honed on early-stage life sciences, particularly in areas of drug discovery and novel therapeutic platforms. He seeks out companies with strong scientific foundations and the potential to address significant unmet medical needs. His deep understanding of the complexities of drug development, from preclinical research to clinical trials, allows him to provide invaluable strategic guidance to portfolio companies. This expertise is crucial for navigating the challenging journey from concept to market in the highly regulated pharmaceutical sector.

De Maeyer's career trajectory is marked by a robust blend of scientific rigor and strategic investment acumen. He holds a PhD in Biomedical Sciences from KU Leuven, providing him with a profound scientific bedrock. Prior to joining Bioqube Ventures, Joris spent a significant portion of his career at Johnson & Johnson. His tenure at Janssen Pharmaceutica, a pharmaceutical company of Johnson & Johnson, saw him in various roles, including Senior Scientist, Project Leader, and Associate Director. In these positions, he was deeply involved in pharmaceutical R&D, project management, and the advancement of drug discovery programs, particularly in neuroscience and immunology. This hands-on experience in a major pharmaceutical corporation equipped him with an insider's perspective on the challenges and opportunities within the industry.

Further solidifying his expertise in venture capital, Joris De Maeyer also served as an Investment Director at Johnson & Johnson Innovation – JJDC, Inc. This role provided him with direct experience in corporate venture investing, where he was responsible for identifying and investing in external innovations that aligned with Johnson & Johnson's strategic interests. This dual background in both large-scale pharmaceutical R&D and direct venture investing makes him a uniquely qualified investor, capable of assessing both the scientific merit and commercial viability of nascent biotech ventures. His contributions help Bioqube Ventures to build a robust portfolio of companies that are not only scientifically sound but also possess strong potential for growth and impact, ultimately aiming to bring transformative therapies to patients worldwide.